Every 8-K that Silo Pharma, Inc. (SILO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SILO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SILO filings page.
Silo Pharma, Inc. (SILO) entered into an asset purchase agreement with Parkview Consulting LLC on August 18, 2026 to acquire certain software, technology, domain names and related intellectual property. In exchange for these assets, Silo Pharma issued 165,000 shares of its common stock to the seller.
The issued shares are subject to a lock-up period starting on the agreement’s effective date and ending on the earlier of 12 months after that date, a defined Change in Control, or written consent of Silo Pharma. During this period, the seller is restricted from transferring or hedging the shares without Silo Pharma’s prior written consent. The agreement includes customary representations, warranties and covenants, and the seller agreed to indemnify Silo Pharma for specified misrepresentations, breaches, third‑party infringement issues and certain misconduct.
Silo Pharma, Inc. reported results of its August 14, 2026 annual shareholder meeting and a related charter change. Shareholders approved an amendment to the Articles of Incorporation to increase the number of authorized common shares from 6,666,667 to 250,000,000, and the company filed a Certificate of Amendment the same day to implement this change. Shareholders re-elected Eric Weisblum, Wayne Linsley, Kevin Muñoz, and Jeff Pavell to the board, ratified Salberg & Company, P.A. as independent registered public accounting firm for the year ending December 31, 2026, and approved an adjournment authorization proposal. A total of 697,308 common shares were represented in person or by proxy, constituting a quorum.
Silo Pharma, Inc. entered into securities purchase agreements with institutional investors for a private placement of its equity and warrants. The structure includes 124,000 shares of common stock at $6.452 per share and pre-funded warrants to purchase up to 495,965 shares of common stock at $6.4519 per warrant, together covering 619,965 shares. Investors also received Series A-3 and Series A-4 warrants to purchase up to 619,965 shares each, all with an exercise price of $6.21 per share, exercisable immediately, with expirations five years and eighteen months, respectively, after the effective date of a resale registration statement. Silo expects aggregate gross proceeds of about $4 million and net proceeds of approximately $3.5 million, and may receive up to roughly $7.7 million in additional gross proceeds if all warrants are exercised for cash. H.C. Wainwright & Co. acted as exclusive placement agent and received a cash fee and warrants for 46,497 shares at an exercise price of $8.065. Net proceeds are intended for working capital and general corporate purposes.
Silo Pharma, Inc. has regained compliance with the Nasdaq minimum bid price requirement. Nasdaq’s Listing Qualifications Staff confirmed that the company’s common stock closed at or above $1.00 per share from June 3, 2026 through June 16, 2026, satisfying Listing Rule 5550(a)(2).
As a result, Silo’s common stock will continue trading on the Nasdaq Capital Market and Nasdaq now considers the matter closed. The company highlighted continued progress toward a first-in-human clinical trial for its PTSD candidate SPC-15 and ongoing development of its AI agents platform QwikAgents.
Silo Pharma, Inc. has implemented a 1-for-15 reverse stock split of its common stock, reclassifying every 15 issued and outstanding shares into one share with the same par value.
At the same time, the company proportionately reduced its authorized common stock to 6,666,667 shares. The reverse split became effective on June 2, 2026, with split-adjusted trading on Nasdaq beginning June 3, 2026 under the existing symbol SILO and a new CUSIP. Outstanding options, warrants, and equity plan reserves were adjusted proportionately, and fractional shares were rounded up to the next whole share. Existing registration statements on Forms S-1 and S-3 are automatically amended so that the amount of shares covered is reduced in line with the 1-for-15 ratio under Rule 416(b).
Silo Pharma is implementing a 1-for-15 reverse stock split of its common stock, with a concurrent proportional cut in authorized shares. The split becomes effective as of 4:01 p.m. Eastern Time on June 2, 2026, and shares will begin trading on a post-split basis on June 3, 2026 under the same symbol, SILO.
Every 15 pre-split shares will be exchanged for 1 post-split share, with fractional positions rounded up to the next whole share. The company expects issued and outstanding shares to decrease from approximately 16.267 million to about 1.084 million. Authorized common stock will be adjusted to 6,666,667 shares, and the share amounts and exercise prices for equity awards, warrants, and plan reserves will be adjusted proportionately.
Silo Pharma, Inc. entered into an asset purchase agreement to acquire the software for the QwikAgents web-based application and related domain names from Many Ads Inc. In exchange for these assets, Silo issued 2,100,000 shares of its common stock to the seller.
The agreement includes customary representations, warranties and covenants, and the seller agreed to indemnify Silo for issues such as misrepresentations, software infringement, and specified misconduct. The shares were issued in a private, unregistered transaction relying on a securities law exemption.
Silo Pharma, Inc. reported two equity-related actions. The company issued 848,320 shares of common stock to its investor relations consultant as a $250,000 commitment fee, valued at $0.2947 per share, in connection with restarting a service agreement. The issuance is an unregistered transaction under Section 4(a)(2) of the Securities Act and provides no cash proceeds to the company.
The board of directors also approved a stock repurchase program authorizing the company to buy back up to $1 million of its common stock through open market or privately negotiated transactions. Silo Pharma had 13,318,273 shares outstanding as of November 13, 2025, providing context for the potential scale of repurchases.
Silo Pharma (SILO) reported results from its October 24, 2025 annual meeting. Shareholders approved giving the Board discretionary authority to effect a reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-20, without reducing the authorized shares, which may be effected at any time before October 24, 2026.
Shareholders also approved an amendment to the 2020 Omnibus Equity Incentive Plan to increase the stock reserve to 1,400,000 shares from 470,000. All four directors—Eric Weisblum, Wayne Linsley, Kevin Muñoz and Jeff Pavell—were re-elected, and Salberg & Company, P.A. was ratified as independent auditor for fiscal 2025. An adjournment proposal was approved as well. A quorum of 5,142,415 shares was represented in person or by proxy.
Silo Pharma, Inc. entered into a securities purchase agreement with institutional investors to raise approximately $2.5 million in gross proceeds. The company sold 2,857,143 shares of common stock at $0.875 per share under its effective shelf registration statement.
For each share purchased, investors received an unregistered warrant to buy one additional share of common stock at an exercise price of $0.75 per share. These warrants are exercisable immediately and expire five years after a registration statement covering the warrant shares becomes effective.
Silo engaged H.C. Wainwright & Co. as exclusive placement agent, agreeing to pay cash fees totaling 8.5% of gross proceeds and to issue placement agent warrants for up to 214,285 shares at an exercise price of $1.0938 per share. The company plans to use net proceeds for working capital and general corporate purposes and agreed to short-term restrictions on issuing additional equity and a one-year prohibition on variable rate transactions.
Silo Pharma (SILO) filed an 8-K to disclose a strategic shift toward digital assets. On 4 Aug 2025 the Board formed a Cryptocurrency Advisory Board of up to three members to guide a newly adopted cryptocurrency treasury strategy. The Board simultaneously appointed Corwin Yu as the first advisor and executed an agreement granting him 45,000 stock options at an exercise price of $0.7757. The options vest in 12 equal monthly tranches under the Amended & Restated 2020 Omnibus Equity Incentive Plan. A press release announcing the initiative was issued on 5 Aug 2025 and filed as Exhibit 99.1.
No financial results, guidance, or capital-raising transactions were reported. The filing is limited to governance changes and does not alter prior disclosures.